|
Donate Contact
us Home |
 |
|
|
 |
About
the Support Group |
 |
How
to join |
 |
Newsletters |
 |
Annual
Review |
 |
Information
|
 |
Meetings |
 |
Research |
 |
Fundraising |
 |
Donations |
 |
Community |
| Information
|
||||
| |
This page contains details of published work
by doctors and scientists known to the Myositis Support Group. Some
of the work in these papers was performed with financial assistance
from the Myositis Support Group. Please remember the information
below is scientific text and often preliminary observations. You
can search work published in medical and scientific journals at
www.pubmed.com
and a medical encyclopaedia is available at http://www.nlm.nih.gov/medlineplus/encyclopedia.html
Dr Hector Chinoy and Dr Robert Cooper Tumour
necrosis factor-alpha single nucleotide polymorphisms are not independent
of HLA class I in UK Caucasians with adult onset idiopathic inflammatory
myopathies. Interferon-Gamma and Interleukin-4 Gene
polymorphisms in UK caucasian idiopathic inflammatory myopathy patients. Monocyte chemotactic protein-1 single
nucleotide polymorphisms do not confer susceptibility for the development
of adult onset polymyositis/dermatomyositis in UK Caucasians. The diagnostic utility of myositis autoantibody
testing for predicting the risk of cancer-associated myositis. In adult onset myositis, the presence
of interstitial lung disease and myositis specific/associated antibodies
are governed by HLA class II haplotype, rather than by myositis
subtype. Have recent immunogenetic investigations
increased our understanding of disease mechanisms in the idiopathic
inflammatory myopathies?
Professor David Scott and/or Dr Yuen-Li Chung
Creatine
supplements in patients with idiopathic inflammatory myopathies
who are clinically weak after conventional pharmacologic treatment:
Six-month, double- blind, randomized, placebo-controlled trial. Use of imaging to assess patients with
muscle disease. Urinary levels of creatine and other
metabolites in the assessment of polymyositis and dermatomyositis. A comparative study of outcome in myositis
and other musculoskeletal disorders assessed using the Nottingham
health profile. In vivo proton magnetic resonance spectroscopy
in polymyositis and dermatomyositis: a preliminary study.
Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database of Systematic Reviews, July 2005. PubMed Abstract Treatment of dermatomyositis and polymyositis.
Treatment of inflammatory myopathies. Postgraduate Medical Journal, July 2006. PubMed Abstract Making sure the treatment of Myositis
does not get “lost in translation”. Pregnancy outcome in adult-onset idiopathic
inflammatory myopathy. Outcome in patients with idiopathic inflammatory
myositis: morbidity and mortality Assessment of inflammatory myositis. Myositis overlap syndromes.
Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford), February 2005. Paper available on the Journal’s Website
Dr Neil McHugh, Dr Zoe Betteridge and Dr Harsha
Gunawardena Anti-synthetase
syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase
(anti-Zo) associated with polymyositis and interstitial pneumonia.
Dr Lucy Wedderburn and/or Dr Clarrisa Pilkington
International
consensus on a proposed score system for muscle biopsy evaluation
in patients with juvenile dermatomyositis: A tool for potential
use in clinical trials. An international consensus survey of
the diagnostic criteria for juvenile dermatomyositis (JDM). Quantitative assessments of the effects
of a single exercise session on muscles in juvenile dermatomyositis. Paediatric idiopathic inflammatory muscle
disease: recognition and management. Paediatric idiopathic inflammatory muscle
disease. Intravenous cyclophosphamide pulse therapy
in juvenile dermatomyositis. A review of efficacy and safety. MHC Class I overexpression on muscles
in early juvenile dermatomyositis.
Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies Medicine (Baltimore), March 2006. PubMed Abstract Seasonal influence on the onset of idiopathic
inflammatory myopathies in serologically defined groups. Outcomes and disease activity measures
for assessing treatments in the idiopathic inflammatory myopathies. Polymyositis: an over diagnosed entity Diagnostic criteria for polymyositis
and dermatomyositis. Idiopathic inflammatory myopathies: a
treatment update. Idiopathic inflammatory myopathy: management
and prognosis. Current approach to the treatment of
polymyositis and dermatomyositis.
Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis Research & Therapy, March 2007. PubMed Abstract Limited effects of high-dose intravenous
immunoglobulin (IVIg) treatment on molecular expression in muscle
tissue of patients with inflammatory myopathies. The heart in dermatomyositis and polymyositis. Signs of inflammation in both symptomatic
and asymptomatic muscles from patients with polymyositis and dermatomyositis. Interstitial lung disease in polymyositis
and dermatomyositis. The role of exercise in the rehabilitation
of idiopathic inflammatory myopathies.
Immunogenetic risk and protective factors
for juvenile dermatomyositis in Caucasians. International consensus guidelines for
trials of therapies in the idiopathic inflammatory myopathies. International consensus outcome measures
for patients with idiopathic inflammatory myopathies. Development
and initial validation of myositis activity and damage indices in
patients with adult onset disease. Defining Clinical Improvement in Adult
and Juvenile Myositis Proposed preliminary core set measures
for disease outcome assessment in adult and juvenile idiopathic
inflammatory myopathies. Autoantibody profiles in the sera of
European patients with myositis.
Genetics of inclusion-body Myositis - M Needham Muscle & Nerve, March 2007. PubMed Abstract Intravenous immune globulin in hereditary
inclusion body myopathy: a pilot study - S
Sparks Potential therapeutic targets for idiopathic
inflammatory myopathies - JL De Bleecker Therapeutic options in autoimmune inflammatory
myopathies (dermatomyositis, polymyositis, inclusion body myositis) - D Pongratz.
Sporadic inclusion body myositis--diagnosis,
pathogenesis and therapeutic strategies - M Dalakas. Safety and efficacy of submaximal eccentric
strength training for a subject with polymyositis - M Harris-Love |
|
||
|
||||
   
 |